Introduction

For life sciences companies, a capital raise is the engine that funds research, clinical trials, and the long road to commercialization. Whether the round is venture, private equity, growth capital, or a strategic partnership, the process puts your most sensitive information in front of outside parties: financial models, intellectual property, and clinical trial data. That makes every life sciences capital raise a security exercise as much as a financing one.

Managing sensitive data during a life sciences capital raise means balancing two competing pressures. Investors need enough transparency to write a recommendation. The company needs to keep its IP, patient data, and competitive position from leaking, getting copied, or breaching HIPAA, GDPR, or 21 CFR Part 11. The companies that close cleanly are the ones that solve the security problem before the first NDA goes out. This post covers what investors typically ask for, the risks that come with sharing it, and how Govern 365 keeps the process tight from teaser to term sheet.

What Do Investors Ask For During a Life Sciences Capital Raise?

In a life sciences capital raise, investors typically request nine categories of information: corporate documents, the pitch deck, the financial model and cap table, the IP portfolio, clinical and scientific data, regulatory compliance records, the business development plan, key personnel bios, and term sheet documents in later stages. The depth of detail scales with the funding stage and the investor’s seriousness.

Corporate documents: formation papers, shareholder and stock issuance agreements, material contracts, employee and confidentiality agreements.
Pitch deck: problem, solution, market overview, competitive position, traction, team, financials, and the investor offer.
Financial model and cap table: revenue projections, cash burn rate, runway, pre-money and post-money valuation, option pool, key KPIs.
IP portfolio: patents, trademarks, copyrights, licensing agreements, a freedom-to-operate (FTO) opinion, NDA framework, pending or potential IP litigation.
Clinical and scientific data: trial phase results, methodology, supplemental summary deck, peer-reviewed publications.
Regulatory compliance: 21 CFR Part 11 records, FDA correspondence, EMA and other national filings, audit reports, HIPAA and GDPR controls, employee training records.
Business development plan: market sizing, competitive analysis, GTM strategy, partnership pipeline, sales cycle assumptions.
Key personnel bios: CVs and credentials for the executive team, scientific advisors, and critical technical staff.
Term sheet documents (later stages): shareholders agreement, subscription agreement, deed of accession, prospectus for public raises.

Not every investor sees all nine at once. Early-stage conversations stay at the pitch deck and high-level financials. Once an NDA is signed and interest hardens, you open access to IP detail, clinical specifics, and the cap table. By the time term sheets are circulating, late-stage diligence parties get the full corporate and regulatory file. Done well, this staged release builds investor confidence without exposing more than the moment requires. Done poorly, with emailed PDFs, shared drive folders carrying broken permissions, or files left behind on someone’s laptop, it leaks competitive intelligence and creates regulatory exposure that follows the company for years. The next section covers the three risks that show up most often.

Challenges in Data Management During Capital Raises

1. Protecting Intellectual Property (IP):

Intellectual property is often a life sciences company’s most valuable asset. During a capital raise, potential investors will want to review the company’s IP portfolio, including patents, research data, and proprietary technologies. However, sharing IP with external parties introduces the risk of theft or unauthorized use. Companies need to ensure that their IP remains protected while still providing investors with enough information to evaluate the company’s value.

2. Managing Financial Transparency

Investors will also require access to detailed financial information, including revenue projections, funding needs, and cost structures. While transparency is necessary to secure funding, companies must also protect their financial data from unauthorized access or misuse. Sensitive financial documents, such as pitch decks and financial models, should be shared securely, with tight control over who can view or download them.

3. Ensuring Compliance with Regulatory Requirements

Life sciences companies are subject to strict regulatory requirements, particularly when handling patient data or clinical trial results. During a capital raise, companies may need to share clinical data with investors to demonstrate the effectiveness of their products. Ensuring that this data is shared in compliance with regulations such as HIPAA or GDPR is critical to avoiding legal and reputational risks.

Govern 365’s Solution: How We Protect Sensitive Data During Capital Raises

Govern 365’s secure data room solution is designed to help life sciences companies manage and protect sensitive data during capital raises, providing the tools and features needed to ensure both transparency and security.

1. Role-Based Access Controls

Govern 365 allows life sciences companies to implement role-based access controls, ensuring that only authorized investors can view or download sensitive documents. These controls allow companies to limit access to specific documents based on the investor’s role or stage in the funding process, ensuring that the right information is shared with the right people at the right time.

2. Download Restrictions and Document Expiry

To further protect sensitive data, Govern 365 offers download restrictions and document expiry features. This ensures that documents cannot be downloaded and stored locally on investors’ devices, reducing the risk of unauthorized sharing. Additionally, companies can set documents to expire after a certain period, automatically revoking access once the capital raise is complete.

3. Secure Collaboration Tools

Govern 365 enables secure, real-time collaboration between life sciences companies and investors. Investors can review pitch decks, financial models, and clinical trial data directly within the platform, leave comments, and request additional information—all within a secure, controlled environment. This eliminates the need for external email chains or unsecured file sharing, ensuring that all sensitive data remains protected.

4. Audit Trails and Transparency

Govern 365’s audit trail feature provides full transparency into who has accessed, viewed, or downloaded documents during the capital raise process. This allows companies to track investor engagement and ensures that there is a clear record of all interactions with sensitive data. In the event of a data breach or dispute, these audit trails provide a critical layer of accountability.

Conclusion

Managing sensitive data during a capital raise is a delicate balance between transparency and security. Life sciences companies must provide potential investors with enough information to secure funding while ensuring that intellectual property, financial data, and clinical trial results are protected. Govern 365 provides the secure data room solution that life sciences companies need to navigate the capital raise process with confidence, offering role-based access controls, download restrictions, secure collaboration tools, and audit trails to protect sensitive data at every stage.